Filtered By:
Drug: Norvir
Vaccination: Vaccines
This page shows you your search results in order of date. This is page number 5.
Order by Relevance | Date
Total 270 results found since Jan 2013.
Outpatient Management of COVID-19: Rapid Evidence Review
Am Fam Physician. 2023 Apr;107(4):370-381.ABSTRACTNew COVID-19 variants of concern continue to develop. Incubation period, transmissibility, immune escape, and treatment effectiveness differ by variants of concern. Physicians should be aware that the characteristics of the predominant variants of concern determine aspects of diagnosis and treatment. Multiple testing modalities exist; the most appropriate testing strategy varies depending on the clinical scenario, with factors of test sensitivity, turnaround time, and the expertise required for specimen collection. Three types of vaccines are available in the United States,...
Source: American Family Physician - April 13, 2023 Category: Primary Care Authors: Anthony M Cheng Emily Dollar Heather Angier Source Type: research
Nirmatrelvir/ritonavir (Paxlovid ®): French pharmacovigilance survey 2022
CONCLUSION: Overall, this analysis shows that nirmatrelvir/ritonavir safety profile was conform to current summary of product characteristics (SmPC). The main concern was the risk of DDI. Therefore, SmPC and expert recommendations should be systematically consulted before initiation of this antiviral, which is particularly indicated in polypharmacy patients. A case-by-case multidisciplinary approach including a clinical pharmacologist is required in these complex situations. Blood pressure elevation, confusion, cutaneous reactions and AKIs were the main unexpected ADRs of interest to follow, but need to be confirmed with a...
Source: Therapie - April 3, 2023 Category: Psychiatry & Psychology Authors: Kevin Bihan Lor ène Lipszyc Florian Lemaitre Anne Dautriche Sophie F édrizzi Marina Atzenhoffer Aur élie Vitores Annabelle Page B énédicte Lebrun-Vignes Source Type: research
Outcome of SARS-CoV2 infection in hematopoietic stem cell transplant recipients for autoimmune diseases
J Autoimmun. 2023 Mar 2;136:103024. doi: 10.1016/j.jaut.2023.103024. Online ahead of print.ABSTRACTHematopoietic stem cell transplant (HSCT) recipients may be at high risk of mortality from coronavirus disease 2019 (COVID-19). However, specific data on COVID-19 after treatment with HSCT in patients affected by autoimmune diseases (ADs) are still lacking. In this multicenter observational study of the European Society for Blood and Marrow Transplantation (EBMT), clinical data on COVID-19 in 11 patients affected by severe ADs treated with HSCT (n = 3 allogeneic transplant; n = 8 autologous transplant) are reported. All patie...
Source: Journal of Autoimmunity - March 31, 2023 Category: Allergy & Immunology Authors: Raffaella Greco John A Snowden Nina Simone Knelange Gloria Tridello Carlotta Cacciatore Alienor Xhaard Fabio Ciceri Matthew Collin Christelle Ferra Ann De Becker Manuela Badoglio Dina Averbuch Tobias Alexander Per Ljungman Rafael De la Camara European Soc Source Type: research
